Abstract:Background Prognosis of small (≤2 cm) invasive lung adenocarcinoma remains poor, and identification of high-risk individuals from the patients after complete surgical resection of lung adenocarcinoma has become an urgent problem. YBX1 has been reported to be able to predict prognosis in many cancers (except lung adenocarcinoma) that are independent of TNM (tumor, nodes, metastases) staging, especially small invasive lung adenocarcinoma. Therefore, we examined the significance of YBX1 expression on prognosis and recurrence in patients with small invasive lung adenocarcinoma. Material and methods A total of 75 patients with small invasive lung adenocarcinoma after complete resection were enrolled from January 2008 to December 2010. Immunohistochemical staining was used to detect the expression of YBX1, and receiver operating characteristic curve analysis was performed to precisely assess the overall expression of YBX1. Meanwhile, primary lesions were identified based on the International Association for the Study of Lung Cancer, the American Thoracic Society, and the European Respiratory Society’s classification of lung adenocarcinoma. The effect of different clinicopathological factors on patients’ survival was examined. Furthermore, Western blot analysis was used to show the expression of YBX1 in vitro. Results Sensitivity and specificity of YBX1 for detecting small invasive lung adenocarcinoma from normal surrounding tissue were 66.7% and 74.7% (area under the receiver operating characteristic curve =0.731; P<0.001), respectively. High YBX1 expression was detected in 31 (41.3%) patients, and in A549, H322, Hcc827, and H1299 lung adenocarcinoma cells but not in HLF cells. In addition to sex, age, tumor size, TNM staging, pleural invasion, and lymph node metastasis, the expression of YBX1 was associated with the International Association for the Study of Lung Cancer, the American Thoracic Society, and the European Respiratory Society pathological grade risk (P=0.026) and differentiation (P=0.009). The patients with low YBX1 expression lived longer than those with high expression (5-year overall survival: 52.3% vs 79.0%; P=0.039) and showed fewer recurrences (P=0.024). In multivariate analyses, high YBX1 expression (odds ratio =2.737; 95% confidence interval: 1.058–7.082; P=0.038) was shown as an independent risk factor of overall survival but not of disease-free survival (odds ratio =1.696; 95% confidence interval: 0.616–4.673; P=0.307). Conclusion YBX1 is an important predictor for the prognosis in patients with small invasive lung adenocarcinoma after complete resection.

Y-Box-Binding Protein-1 And E-Cadherin Are Potential Prognostic Factors In Human Bladder Carcinoma

Effects of Y Box Binding Protein-1 in Progression and Prognosis of Cholangiocarcinoma.

Increased Expression of HMGB1 is Associated with Poor Prognosis in Human Bladder Cancer

CK20 and Ki-67 As Significant Prognostic Factors in Human Bladder Carcinoma

High Expression of Y-box-binding Protein 1 Correlates with Poor Prognosis and Early Recurrence in Patients with Small Invasive Lung Adenocarcinoma

Single-cell Sequencing Data Reveals Aggressive CD68-type Macrophages and Prognostic Models in Bladder Cancer.

Overexpression of high mobility group box 1 and 2 is associated with the progression and angiogenesis of human bladder carcinoma.

Extracellular matrix protein 1 (ECM1) is associated with carcinogenesis potential of human bladder cancer.

The prognostic significance of ABCG1 for patients with Bladder cancer

High Expression of Y-Box-Binding Protein-1 is Associated with Poor Survival in Resectable Esophageal Squamous Cell Carcinoma

Elevated nuclear YBX1 expression and the clinicopathological characteristics of patients with solid tumors: a meta-analysis.

Identification of MAN1B1 As a Novel Marker for Bladder Cancer and Its Relationship with Immune Cell Infiltration

Identification and validation of basement membrane-related genes predicting prognosis and immune infiltration associated with bladder cancer

The Clinical Significance and Prognostic Value of HER2 Expression in Bladder Cancer: A Meta-Analysis and a Bioinformatic Analysis

Novel Potential Biomarkers Associated With Epithelial to Mesenchymal Transition and Bladder Cancer Prognosis Identified by Integrated Bioinformatic Analysis

Comprehensive Analysis Reveals the Value of the Expression of Chromobox Family Members for Bladder Urothelial Carcinoma Prognosis

EPDR1 levels and tumor budding predict and affect the prognosis of bladder carcinoma

FOXM1 and β-catenin are potential prognostic markers in muscle-invasive bladder carcinoma

The Clinical Implications and Molecular Mechanism of CX3CL1 Expression in Urothelial Bladder Cancer

Y-Box Binding Protein 1 Regulates Angiogenesis in Bladder Cancer via miR-29b-3p-VEGFA Pathway

Effect of Y-box binding protein 1 on tumor and its research